Accessibility Menu
Bio-Rad Laboratories Stock Quote

Bio-Rad Laboratories (NYSE: BIO)

$333.10
(0.6%)
+1.83
Price as of October 22, 2025, 11:59 a.m. ET

KEY DATA POINTS

Current Price
$333.1
Daily Change
(0.6%) +$1.83
Day's Range
$327.47 - $336.79
Previous Close
$331.27
Open
$329.88
Beta
0.94
Volume
3,638
Average Volume
255,025
Market Cap
9B
Market Cap / Employee
$331.27M
52wk Range
$211.43 - $387.99
Revenue
-
Gross Margin
0.54%
Dividend Yield
N/A
EPS
$11.73
CAPs Rating
-
Industry
Life Sciences Tools and Services

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Bio-Rad Laboratories Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
BIO-3.45%-42.79%-10.57%+12,863%
S&P+15.06%+95.03%+14.29%+5,893%

Bio-Rad Laboratories Company Info

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$651.60M2.1%
Gross Profit$345.40M-2.9%
Gross Margin53.01%-2.7%
Market Cap$6.57B-15.7%
Market Cap / Employee$0.85M0.0%
Employees7.7K-4.1%
Net Income$317.80M114.7%
EBITDA$130.10M-11.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$371.30M-8.8%
Accounts Receivable$469.90M5.5%
Inventory798.8-0.6%

Liabilities

Q2 2025YOY Change
Long Term Debt$1.37B1.1%
Short Term Debt$40.60M-3.3%

Ratios

Q2 2025YOY Change
Return On Assets3.21%15.4%
Return On Invested Capital1.14%-10.6%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$70.80M27.9%
Operating Free Cash Flow$116.50M19.3%

Valuation

MetricQ2 2025YoY Change
Price to Earnings20.57-
Price to Book1.391.231.041.0016.00%
Price to Sales3.633.582.682.57-14.99%
Price to Tangible Book Value1.561.361.161.1219.38%
Price to Free Cash Flow TTM37.9831.8219.1517.71-69.31%
Enterprise Value to EBITDA63.5866.4262.0050.74-0.96%
Free Cash Flow Yield2.6%3.1%5.2%5.6%225.80%
Return on Equity-9.8%-24.1%-27.5%4.6%-126.36%
Total Debt$1.39B$1.38B$1.37B$1.41B0.99%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.